See how it's done: GSK beats data access path
This article was originally published in Scrip
GlaxoSmithKline, now the industry leader on the clinical trial transparency front, has given more details of its system for providing raw patient-level data to researchers for further analysis, including strict controls over who can access the data and to what end. It has also named the members of the panel that will vet research proposals.
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.